FinnCap Begins Coverage on Shield Therapeutics (STX)

FinnCap began coverage on shares of Shield Therapeutics (LON:STX) in a research note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports. The brokerage issued a corporate rating and a GBX 200 ($2.61) price target on the stock.

STX has been the subject of several other reports. Peel Hunt restated a buy rating on shares of Shield Therapeutics in a research report on Wednesday, April 24th. Liberum Capital restated a buy rating on shares of Shield Therapeutics in a research report on Wednesday, April 3rd.

STX opened at GBX 100 ($1.31) on Tuesday. The firm has a market cap of $117.09 million and a PE ratio of -66.67. Shield Therapeutics has a 52-week low of GBX 24 ($0.31) and a 52-week high of GBX 100 ($1.31).



In other Shield Therapeutics news, insider Mark Sampson acquired 22,042 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was acquired at an average cost of GBX 91 ($1.19) per share, for a total transaction of £20,058.22 ($26,209.62). Also, insider James M. Karis acquired 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were acquired at an average price of GBX 81 ($1.06) per share, with a total value of £3,240 ($4,233.63).

Shield Therapeutics Company Profile

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Featured Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.